Uppsala, Sweden – 2024-07-26
A significant step forward in personalized healthcare is being made possible with Eurostars funding for the further development of the DIAMPS project.
This consortium, commercially led by Probingon AB, is creating a novel, handheld muscle-sensing device that promises to revolutionize chronic disease management. Quantifying Muscle Health with a Non-Invasive Approach.
Current methods for assessing muscle mass and quality often rely on techniques like X-rays, ultrasounds, and MRIs. While valuable, these methods can be operator-dependent, often involve ionizing radiation, have high costs, and limited accessibility, hindering continuous monitoring for chronic disease patients.
The DIAMPS device offers a groundbreaking solution. Utilizing safe, non-ionizing microwave technology, the innovative DIAMPS device will provide a highly accurate and portable method for measuring muscle health at the point of care. This empowers healthcare providers in various settings—from hospitals and clinics to community screenings—to deliver preventive and personalized care.
Transforming Healthcare Delivery
“We are thrilled to receive Eurostars funding for DIAMPS,” says Mark Schneider, CEO of Probingon AB, the company leading the consortium. “This innovative device has the potential to transform how we manage chronic conditions by enabling early detection, improved diagnosis, and continuous monitoring of muscle health.”
DIAMPS aligns perfectly with the European Union’s focus on preventive and continuous healthcare. This achievement underscores the EU’s commitment to fostering R&D that drives a healthier future for all.
The DIAMPS Consortium: A Collaborative Effort
The success of DIAMPS is a testament to the collaborative spirit of the consortium, which includes:
· EVALAN (CEO: Mr. Henk Schwietert)
· Hytton Technologies AB (CEO: Mr. Siju John)
· Probingon AB (CEO: Mr. Mark Schneider)
· Maastricht UMC+ (MUMC), Faculty of Health, Medicine and Life Sciences (Medical Lead: Dr. Taco Blokhuis)
· Uppsala University Microwave in Medical Engineering Group (Scientific Lead: Dr. Robin Augustine)
About Probingon AB
Probingon AB is a clinical-grade wearable and IoMT diagnostics company based in Uppsala, Sweden. Playing a leading role in the DIAMPS consortium, Probingon is committed to commercializing and launching this groundbreaking device, enabling the future of preventive and continuous healthcare.
Media Contact:
Mark Schneider, CEO mark@probingon. com
